# Pathios Therapeutics

Source: https://onco.cc/companies/pathios-therapeutics/  
OnCo record `pathios-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pathios Therapeutics makes PTT-4256, a tablet designed to stop the acidic surroundings of a tumour from switching off the immune cells inside it. It is in an early trial in people with advanced solid tumours.

## Summary

Pathios Therapeutics Ltd is an Oxford, UK, drug discovery company established in 2017, according to the company. It targets GPR65, an acid-sensing G protein-coupled receptor on immune cells; the company's case is that the low pH of solid tumours signals through GPR65 to push T cells, NK cells, dendritic cells and especially macrophages towards an immunosuppressed, pro-tumour state. Its lead asset PTT-4256 is an orally bioavailable, selective GPR65 inhibitor. The company says it has raised a total of $58 million in venture funding, most recently a Series B to take PTT-4256 into the clinic. Its first registered cancer trial, NCT06634849 (RAISIC-1), a modular phase 1/2 dose-finding study of once-daily oral PTT-4256 in solid tumours at Australian sites, sponsored by its Australian subsidiary Pathios Therapeutics Pty Ltd, was posted on ClinicalTrials.gov in October 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Pathios Therapeutics Ltd
- HQ: Oxford
- Type: biotech
- Website: https://pathios.com/

## Notes

- OnCo has no target record for GPR65 and no technology record for GPCR-directed small molecules, so neither is linked.
- Investor names on the company's investors page are shown as logos and were not read.
- Company website read on 29 October 2026.

## Sources

- Official website: https://pathios.com/
- About Pathios: https://pathios.com/about-us/

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- trials: [An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).](https://onco.cc/trials/nct06634849/)

---
JSON: https://onco.cc/api/v1/entities/pathios-therapeutics.json